SynthesisAmerican journal of clinical dermatology2023
Do Biologic Treatments for Psoriasis Lower the Risk of Psoriatic Arthritis? A Systematic Review.
Synthesis in American journal of clinical dermatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.
- Impact of Biologic Therapies on the Risk of Progression from Psoriasis to Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Cohort Studies.American journal of clinical dermatology · 2026Pooled it
- Arthralgia and Ultrasound Characteristics of Subclinical Psoriatic Arthritis: A Cross-Sectional Study Based on the SPAWCH Cohort.The Journal of dermatology · 2026Article
- Diagnosis and therapeutic management of psoriatic arthritis: summary of 2024 update of the Spanish clinical practice guideline (ESPOGUIA).Therapeutic advances in musculoskeletal disease · 2026Review
- Navigating the Journey in Psoriatic Arthritis: Matching the Right Patient, the Right Drug, and the Right Time.Journal of clinical medicine · 2025Article
- Psoriatic arthritis incidence and prevalence trajectory in Poland-public-payer, national-level, long-term data.Rheumatology international · 2025Article
- Disease Modification in Psoriasis: Future Prospects for Long-Term Remission.American journal of clinical dermatology · 2025Review
- High Systemic Disease Risk and Therapeutic Delays in Plaque Psoriasis: A Retrospective Analysis of Apremilast Use in the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).Dermatology and therapy · 2025Article
- Digital technologies in psoriasis management: from precision diagnosis to therapeutic innovation and holistic care.Frontiers in digital health · 2025Review
- From psoriasis to psoriatic arthritis: epidemiological insights from a retrospective cohort study of 74,046 patients.Frontiers in medicine · 2024Article
- Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: limitations and opportunities.RMD open · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveThe effectiveness of biologic treatments in slowing the progression of psoriatic arthritis is well established, but there is limited and conflicting evidence on their ability to prevent the development of psoriatic arthritis in patients with psoriasis. The objective of this review was to evaluate the role of biologic treatment for psoriasis in preventing or delaying subsequent psoriatic arthritis.
methodsA literature search was performed using MEDLINE (PubMed), Embase, Web of Science, and the Cochrane Library for studies published in English from database inception to March 2022 that statistically compared the risk of psoriatic arthritis in patients aged > 16 years who were previously treated with biologic disease-modifying antirheumatic drugs or with other drugs for skin psoriasis.
resultsFour articles were eligible for analysis, all retrospective cohort studies. Three were conducted in preselected patients attending dermatology or dermatology-rheumatology collaboration centers and one was a large population-based study. In three studies, a primary two-step statistical analysis yielded a significantly lower risk of psoriatic arthritis in patients treated with biologic agents. These findings were not supported by the large retrospective electronic health record-based study.
conclusionsBiologic treatments may be effective in preventing the development of psoriatic arthritis in patients with psoriasis. More research is needed given the retrospective cohort design of all studies included in the review limiting the generalizability of the results, and the conflicting results from the registry study. At present, biologic agents should not be prescribed to unselected patients with psoriasis for the sole purpose of preventing psoriatic arthritis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.